Asian witnessed weak sentiment in Thursday's trading as markets digested the Fed's widely expected rate cut, the forward guidance for 2026 and beyond, as well as the extent of dissent in the FOMC decision. Though markets turned cautious in the aftermath of the Fed's projection of a single rate cut for 2026, losses were limited by the less-than-expected hawkishness in the Fed's guidance.China's Shanghai Composite Index lost 27 points or 0.70 percent to finish trading at 3,873.32, versus the previous close o ...

Group 1 - Fintech company Findi is facing legal issues after a user claimed misconduct on forums, prompting the company's legal team to get involved [2] - PainChek's app for aged care homes received FDA approval, leading to increased attention as the company now focuses on sales [3] - Mesoblast's stock is gaining traction again as its stem cell drug Ryoncil shows sales momentum in the USA [4] Group 2 - Race Oncology's stock reached an all-time high after revealing the mechanism of action for its drug Bisantrene, which is believed to be a chemotherapy drug without side effects [4] - Trigg Minerals is exploring options for a NASDAQ listing, including a potential SPAC listing, as it targets the US critical metals market [5] - Fintech Stakk remains popular after securing deals with Robinhood and T-Mobile, alongside a $15 million placement currently under review [6]

Financial Data and Key Metrics Changes - Revenue from cell therapy products increased to $17.2 million, up 191% from the prior year, driven by the successful launch of Ryoncil [12][15] - Net operating cash spend for the year was $50 million, consistent with the prior year, despite investments in commercial team build-out and product launch activities [13][15] - Cash on hand as of June 30 was $162 million [13] Business Line Data and Key Metrics Changes - Ryoncil generated $13.2 million in gross sales and $11.3 million in net sales after a 14.6% gross to net adjustment [12] - Cost of revenues related to product sales was $1.2 million, representing 10% of net product sales, resulting in a gross margin of 90% [15] - Selling, general, and administrative expenses rose to $39.3 million, an increase of $14.3 million from FY 2024, primarily due to the commercial team build-out [15] Market Data and Key Metrics Changes - The addressable market for Ryoncil in pediatric acute graft versus host disease (GVHD) is significant, with potential label extensions in adult populations and other inflammatory diseases [9][10] - The addressable market for heart failure with reduced ejection fraction and chronic low back pain is estimated to exceed $10 billion each [9] Company Strategy and Development Direction - The company aims to expand Ryoncil's label to include adult patients with GVHD and other inflammatory conditions, leveraging existing pediatric treatment centers [24][25] - Plans to initiate pivotal studies for Ryoncil in inflammatory bowel disease and chronic low back pain are underway, targeting significant unmet medical needs [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Ryoncil and its potential to transform the company from an R&D-focused entity to a commercial biotech organization [87] - The company is focused on building a robust commercial infrastructure to support ongoing sales growth and market access [76][82] Other Important Information - Ryoncil became commercially available on March 28, 2025, shortly after receiving FDA approval in December 2024 [10] - The company has onboarded 32 transplant centers in the U.S. and aims to reach 45 centers that account for 80% of pediatric bone marrow transplants [10][11] Q&A Session Summary Question: Timeline for adult GVHD label extension - Management expects to commence an adult acute GVHD trial this quarter, working with the NIH-funded Bone Marrow Transplant Clinical Trials Network [46][48] Question: Progress on Phase III chronic lower back pain trial - Enrollment is ongoing with nearly 40 sites, and management is optimistic about achieving similar outcomes as in previous trials [50][51] Question: Monthly treatment kits administered and inventory dynamics - Treatment kits are stocked based on weight bands, with replenishment occurring as children are treated [56][57] Question: Gross to net dynamics and adult GVHD trial design - Management expects gross to net adjustments to remain flat and plans to include patients on Jakafi in the adult trial to maximize market potential [59][60] Question: Details on adult study and trial design - The FDA is aligned with the company on trial design, focusing on early intervention in severe adult populations [64][66] Question: Timeline for inflammatory bowel disease trials - A KOL group is designing the trial, with plans to use both local and intravenous delivery methods [68] Question: Market access progress - The company has engaged with over 97 payers, achieving coverage for over 250 million lives, with Medicaid coverage in place across all states [82][83]

ASXNSB Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs August 2025 TechKnow Invest Roadshow Nathan Smith – Chief Executive Officer 1 For personal use only Disclaimers For personal use only Presentation Information This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information nece ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [6]. Core Insights - The report emphasizes the significant progress in stem cell therapy across multiple indications, suggesting a focus on companies like Jiuzhitang and Zhongyuan Qihe [3][5]. - The investment strategy is centered around three main themes: innovation, recovery, and policy support, with a strong emphasis on innovative drugs as the most clear long-term trend in the pharmaceutical sector [5]. Summary by Sections 1. Investment Focus on Pharmaceutical Combinations - The recommended investment combination outperformed the pharmaceutical index by 2.8 percentage points and the broader market by 3.1 percentage points last week [12]. 2. Stem Cell Therapy: Policy and Progress - China's regenerative medicine has reached a world-leading level, with clear industry policies marking a golden development period for stem cell therapy [17]. - Multiple indications are seeing critical advancements, with expectations for key data releases this year [17]. - The first domestically approved stem cell therapy was launched in January 2025, marking a historic turning point for the industry [6][17]. 3. Weekly Market Review and Hotspot Tracking (May 12-16, 2025) - The CITIC Pharmaceutical Index rose by 1.4%, outperforming the CSI 300 Index by 0.3 percentage points, ranking 10th among CITIC's primary industry classifications [61]. - The pharmaceutical sub-sectors showed positive performance, with chemical raw materials up by 2.79% and traditional Chinese medicine up by 2.01% [64].